Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -3.46% is 45% above its 5-year average of -6.26%, around the middle of its 5-year range (-15.01%–3.43%).
822.67% below its 12-month average of -0.37%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -0.37%.
RETURN ON ASSETS (ROA)
-3.46%
RETURN ON ASSETS (ROA) AVG TTM
-0.37%
RETURN ON ASSETS (ROA) AVG 3Y
-7.11%
RETURN ON ASSETS (ROA) AVG 5Y
-6.26%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-822.67%
CURRENT VS 3Y AVG
+51.34%
CURRENT VS 5Y AVG
+44.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
+88.73%
vs the sector median at left
Castle Biosciences, Inc.
Market Cap
$1.04B
Return on Assets (ROA)
-3.46%
TTM Avg
-0.37%
3Y Avg
-7.11%
5Y Avg
-6.26%
Market Cap
$1.04B
Return on Assets (ROA)
-10.18%
TTM Avg
-8.89%
3Y Avg
-12.61%
5Y Avg
-16.81%
Market Cap
$1.04B
Return on Assets (ROA)
-43.17%
TTM Avg
-16.38%
3Y Avg
-11.13%
5Y Avg
-30.16%
Market Cap
$1.03B
Return on Assets (ROA)
-0.20%
TTM Avg
-7.25%
3Y Avg
-2.02%
5Y Avg
0.01%
Market Cap
$1.05B
Return on Assets (ROA)
-6.43%
TTM Avg
-17.46%
3Y Avg
-82.63%
5Y Avg
-55.94%
Market Cap
$1.07B
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$1.02B
Return on Assets (ROA)
-1.53%
TTM Avg
-4.15%
3Y Avg
-5.20%
5Y Avg
-5.20%
Market Cap
$1.01B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
Return on Assets (ROA)
20.05%
TTM Avg
20.12%
3Y Avg
18.47%
5Y Avg
14.51%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.04B | -3.46% | -0.37% | -7.11% | -6.26% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | -10.18% | -8.89% | -12.61% | -16.81% |
| Immatics N.V. (IMTX)vs › | $1.04B | -43.17% | -16.38% | -11.13% | -30.16% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.20% | -7.25% | -2.02% | 0.01% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -6.43% | -17.46% | -82.63% | -55.94% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.07B | -56.27% | -37.98% | -21.94% | -21.15% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -1.53% | -4.15% | -5.20% | -5.20% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 20.05% | 20.12% | 18.47% | 14.51% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $998.31M | -23.69% | -98.11% | -69.18% | -69.18% |
ROA
-3.5%
ROE
-4.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -4.18% |
| 2024-12-31 | 3.43% |
| 2023-12-31 | -12.68% |
| 2022-12-31 | -15.01% |
| 2021-12-31 | -6.76% |
| 2020-12-31 | -2.34% |
| 2019-12-31 | 4.41% |
| 2018-12-31 | -28.42% |
| 2017-12-31 | -125.96% |
